Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GSK
Pharma
GSK CEO targets mature products, procurement for cost savings
GSK's major $2.5 billion cost savings will mainly target better procurement, mature products and the supply chain, CEO Luke Miels said.
Angus Liu
Jul 28, 2026 9:45am
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 2026 9:42am
Nuvalent deal delivers GSK’s first-ever lung cancer approval
Jul 22, 2026 3:15pm
GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia
Jul 17, 2026 9:38am
Merck touts Keytruda front-line win in endometrial cancer subtype
Jul 15, 2026 3:33pm
GSK to seek FDA approval for Jemperli in high-profile cancer use
Jul 13, 2026 10:50am
